Bedaquiline kills persistent Mycobacterium tuberculosis with no disease relapse: an in vivo model of a potential cure | Zendy

Yanmin Hu | Zendy; Henry Pertinez | Zendy; Yingjun Liu | Zendy; Geraint Davies | Zendy; Anthony Coates | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Bedaquiline kills persistent Mycobacterium tuberculosis with no disease relapse: an in vivo model of a potential cure

Author(s) -

Yanmin Hu,

Henry Pertinez,

Yingjun Liu,

Geraint Davies,

Anthony Coates

Publication year - 2019

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkz052

Subject(s) - bedaquiline , ethambutol , regimen , pyrazinamide , medicine , tuberculosis , rifampicin , isoniazid , mycobacterium tuberculosis , culture conversion , pharmacology , surgery , sputum , pathology

Non-replicating persistent Mycobacterium tuberculosis is difficult to kill since the organisms become undetectable using our conventional diagnostic methods and tolerant to anti-TB drugs. Resuscitation-promoting factors (RPFs) have been used to 'wake up' non-replicating persisters, making them easy to detect. Bedaquiline is a novel bactericidal and sterilizing anti-TB drug with the potential to eradicate RPF-dependent persistent M. tuberculosis. We present the first head-to-head comparison between the standard anti-TB regimen and a bedaquiline-modified regimen in eradicating RPF-dependent persistent M. tuberculosis, using the well-defined Cornell Model.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research